Patient enrollment and characteristics
non-DLT
CHRONIC OBSTRUCTIVE PULMONARY DISEASE EXACERBATION
From April 2016–Aug 2019, twenty patients enrolled, including 15 on the dose-finding component and 5 in the expansion cohort. Three patients in the dose-finding phase discontinued treatment early for non-DLT reasons (travel hardship, chronic obstructive pulmonary disease exacerbation, and grade 2 liver function testing (LFT) abnormality) and were replaced. Overall, four patients (1 non-evaluable for DLT or response) were treated at dose level 1, 6 at dose level 2, 5 at dose level 3 (2 non-evaluable for DLT, 1 non-evaluable for response), and an additional 5 patients were treated at dose level 3 in the expansion cohort.Patients included 9 men (45%) and 11 women (55%), with a median age of 76.0 years (range: 62.2–88.9 years). Three patients (15%) had a Zubrod PS of 2, and 17 (85%) had a PS of 0–1. Sixty-five percent of enrolled patients had at least 2 of the three pre-defined high-risk features [size ≥ 2 cm, SUVPatient characteristics